RNAimmune, Inc., a Gaithersburg, Md.-based biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, completed a $2.35m seed financing.
Backers included Terra Magnum Capital Partners.
The company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.
A spin-off entity from Sirnaomics, Inc., led by Dr. Dong Shen, founder and CEO, RNAimmune is a biopharmaceutical company specializing in discovery and development of messenger RNA (mRNA) therapeutics and vaccines. The company leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
RNAimmune is a spin-off venture from Sirnaomics, Inc. having received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. The company has also developed a proprietary A.I. algorithm (ALEPVA) for antigen prediction and vaccine design.
By integrating multiple established platform technologies, the company is aiming to develop a comprehensive mRNA drug discovery and development platform, from which the company will enrich its therapeutic and vaccine product pipeline addressing unmet needs in treatments of viral infections, cancer and rare diseases.